Comparison of epirubicin and vinorelbine with cyclophosphamide, epirubicin, and fluorouracil as neoadjuvant chemotherapy for operable breast cancer

被引:0
|
作者
Han, S. [1 ]
Kwak, K. [1 ]
Kim, J. [1 ]
Kim, J. [1 ]
Park, K. [1 ]
机构
[1] Inje Univ, Sanggye Paik Hosp, Breast Canc Ctr, Seoul, South Korea
来源
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:122 / 122
页数:1
相关论文
共 50 条
  • [31] Primary chemotherapy with epirubicin and vinorelbine in women with locally advanced breast cancer
    Nisticò, C
    De Matteis, A
    Ross, E
    Carnino, F
    Valenza, R
    Agostara, B
    Bria, E
    Farris, A
    Cremonesi, M
    D'Ottavio, AM
    Vaccaro, A
    Garufi, C
    Giunta, S
    Botti, C
    Perrone, F
    Terzoli, E
    ANTICANCER RESEARCH, 2005, 25 (2B) : 1343 - 1348
  • [32] A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer
    Esteban, E
    de Sande, G
    Puertas, J
    Fra, J
    Palacio, I
    Vieitez, JM
    Fernández, JL
    Muñiz, I
    Modollel, A
    Carrasco, J
    Sala, M
    Lacave, AJ
    BREAST CANCER RESEARCH AND TREATMENT, 2000, 62 (02) : 127 - 133
  • [33] Neoadjuvant 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer.
    Heller, W.
    Mazhar, D.
    Ward, R.
    Lowdell, C.
    Dudley, S.
    Sami, S.
    Carlo, P.
    Charles, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S157 - S157
  • [34] Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial
    Kin, Takanori
    Ohtani, Shoichiro
    Maeda, Reina
    Ueno, Ayako
    Fujihara, Miwa
    Takamatsu, Yuri
    Kajiwara, Yukiko
    Ito, Mitsuya
    Kawasaki, Kensuke
    Abe, Keisuke
    Sakata, Yasuhiko
    Hiraki, Koichi
    WORLD JOURNAL OF ONCOLOGY, 2020, 11 (05) : 197 - 203
  • [35] Neoadjuvant docetaxel (DOC 75) followed by fluorouracil, epirubicin, cyclophosphamide (FEC 100) in primary operable breast cancer: results of a multicenter phase II trial
    Sato, N.
    Iwata, H.
    Masuda, N.
    Nakamura, S.
    Yamamoto, N.
    Kuroi, K.
    Kurosumi, M.
    Tsuda, H.
    Akiyama, F.
    Toi, M.
    EJC SUPPLEMENTS, 2008, 6 (07): : 121 - 121
  • [36] Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer
    Hajime Abe
    Tsuyoshi Mori
    Yuki Kawai
    Hirotomi Cho
    Yoshihiro Kubota
    Tomoko Umeda
    Yoshimasa Kurumi
    Tohru Tani
    International Journal of Clinical Oncology, 2013, 18 : 487 - 491
  • [37] Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer
    Abe, Hajime
    Mori, Tsuyoshi
    Kawai, Yuki
    Cho, Hirotomi
    Kubota, Yoshihiro
    Umeda, Tomoko
    Kurumi, Yoshimasa
    Tani, Tohru
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (03) : 487 - 491
  • [38] Primary systemic chemotherapy for operable breast cancer with docetaxel followed by cyclophosphamide, epirubicin, and fluorauracil (DOC-CEF)
    Kikawa, Y.
    Masai, Y.
    Hashimoto, T.
    Nakamoto, Y.
    Nishikawa, H.
    Takahara, S.
    Suwa, H.
    Tachibana, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Cyclophosphamide, epirubicin and fluorouracil followed by docetaxel (CEF-DOC) as preoperative chemotherapy in primary operable breast cancer: Evaluation of chemotherapeutic response by breast MRI.
    Nakamura, S
    Ohno, S
    Toi, M
    Takatsuka, Y
    Kuroi, K
    Iwata, H
    Hisamatsu, K
    Yamazaki, K
    Masuda, N
    Akiyama, F
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 79S - 79S
  • [40] Neoadjuvant chemotherapy with epirubicin-vinorelbine and G-CSF in locoregionally advanced breast cancer: Our experience
    Savarino, A.
    Fabiano, E.
    Maniaci, V
    Puliafito, I
    Sauta, M. G.
    Bene, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 43 - 43